Sharp Therapeutics Corp.

Sharp Therapeutics Corp.

SHRX · V · Healthcare / Biotechnology

1.37CAD+0.00 (0.00%)

Price History

Full chart

Market Stats

Previous Close1.37
Open1.37
Day Range1.37 – 1.37
52-Week Range0.91 – 5.00
Volume0
Market Cap41.20M
P/E (TTM)0.00
Forward P/E0.00
EPS-0.28
Dividend Yield0.00%
Beta-1.15
50-Day Avg1.08
200-Day Avg1.74

About

Sharp Therapeutics Corp., a preclinical-stage drug discovery company, develops therapeutics for genetic diseases. The company engages in the development of the CoreX, a suite of biology technologies that allows the creation of sensitive assays mimicking the genetic disease state, enabling discovery of compounds that correct the mutational defect; AlloChem, a compound library which binds proteins allosterically; and Mine, a custom-built, cloud-distributed analytics platform that captures data for AlloChem compounds in CoreX assays. Sharp Therapeutics Corp. is headquartered in Pittsburgh, Pennsylvania.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEODr. Scott F. Sneddon J.D., Ph.D.
  • Employees0
  • Headquarters2403 Sidney Street, Pittsburgh, PA, United States, 15203, Canada
  • Websitehttps://sharptx.com

Leadership

  • Dr. Scott F. Sneddon J.D., Ph.D.CEO, Chief Science Officer & Director · b. 1963
  • Mr. Edward Jonasson CA CPACFO & Corporate Secretary · b. 1969
  • Mr. Marcel P. Bruchez Ph.D.Scientific Co-Founder & CTO
  • Dr. Alan S. Waggoner Ph.D.Scientific Co-Founder and Chief Architect

Financials

Income Statement

Currency: USD2023-12-312024-12-312025-12-31
Total Revenue000
Operating Income-2.27M-4.55M-5.51M
EBITDA-3.28M-2.99M-5.91M
Net Income-3.56M-3.26M-6.17M
R&D1.73M2.09M3.53M
Interest Expense174.47K170.95K166.89K

Balance Sheet

Currency: USD2023-12-312024-12-312025-12-31
Total Assets1.55M4.55M1.95M
Total Liabilities13.03M1.97M2.13M
Total Equity-11.48M2.58M-176.59K
Cash376.87K3.48M956.60K
Net Debt6.70M--

Cash Flow

Currency: USD2023-12-312024-12-312025-12-31
Operating Cash Flow-1.96M-3.62M-4.83M
Financing Cash Flow2.18M6.73M2.32M
Capital Expenditure10.33K14.49K0
Free Cash Flow-1.97M-3.63M-4.83M
FCF to OCF100.53%100.40%100.00%

Earnings

Report DateNov 26, 2026
EPS Estimate-
EPS Actual-
Surprise-
TimingAfter-hours

Key Statistics & Ratios

Market Cap41.20M
Enterprise Value46.28M
Trailing P/E0.00
Forward P/E0.00
Price / Sales0.00
Price / Book32.69
EPS-0.28
Book Value-0.1021
Revenue (TTM)0
Gross Profit (TTM)0
EBITDA-5.58M
Profit Margin0.00%
Operating Margin0.00%
Return on Equity-3762.21%
Return on Assets-131.63%
Shares Outstanding30.08M
Shares Float17.62M
Beta-1.15
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Stock Splits

  • Jan 27, 20251:10